Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

NCT05554939 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non Hodgkin's Lymphoma

Interventions

BIOLOGICAL: Allogenic CD19 CAR-γδT cell
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Chinese PLA General Hospital